About This CrCl Calculator
This calculator estimates creatinine clearance (CrCl) using the Cockcroft-Gault equation, the most widely referenced formula for CrCl in drug dosing and radiology workflows. It applies IBW/ABW adjustment when height is provided, and translates the computed CrCl into a contrast volume ceiling and nephrotoxicity risk tier for clinical decision support.
Cockcroft-Gault Formula
Derived by Cockcroft and Gault in 1976 from 249 hospitalized patients, this formula remains the reference equation for most drug dosing guidelines despite its age. The sex factor (0.85) corrects for lower average muscle mass in biological females. Weight should be actual body weight unless actual exceeds IBW, in which case adjusted body weight (ABW) should be substituted.
Ideal Body Weight (Devine Formula)
IBW (kg) — Female: 45.5 + 2.3 × (Height_inches − 60)
When actual body weight exceeds IBW, use adjusted body weight (ABW):
The 0.4 correction factor accounts for the partial contribution of adipose tissue to creatinine production in obese patients. Using actual weight in obese patients overestimates CrCl and can lead to toxic drug doses.
Contrast Volume Ceiling — 5×CrCl Rule
The maximum safe iodinated contrast volume (in mL) is estimated as:
This rule, from Cigarroa et al. (1989), was derived in cardiac catheterization patients and has been widely adapted for CT protocols. It bounds the contrast load relative to the kidney's clearance capacity, limiting CI-AKI risk. For example, a patient with CrCl 60 mL/min should receive no more than 300 mL of iodinated contrast. Always confirm institutional protocol limits.
CrCl vs eGFR — When to Use Each
| Feature | Cockcroft-Gault CrCl | CKD-EPI eGFR |
|---|---|---|
| What it estimates | Creatinine clearance (absolute, mL/min) | GFR normalized to 1.73m² BSA |
| Weight variable | Required (use ABW if obese) | Not used |
| Best used for | Drug dosing, contrast volume ceiling | CKD staging, contrast safety thresholds |
| Guideline endorsement | FDA drug labels, pharmacokinetic studies | KDIGO, NKF, ACR contrast guidelines |
| Race correction | None | None (2021 update removed race) |
Nephrotoxicity Risk Tiers
| CrCl (mL/min) | Risk Tier | Iodinated Contrast | Max Volume |
|---|---|---|---|
| ≥ 60 | Low risk | Standard precautions | ≥ 300 mL (5×CrCl) |
| 30–59 | Moderate risk | IV hydration; volume limit; hold metformin | 150–295 mL (5×CrCl) |
| 15–29 | High risk | Nephrology consult; risk-benefit discussion; minimize volume | 75–145 mL (5×CrCl) |
| < 15 | Very high risk | Generally avoid; dialysis patients may receive with coordination | < 75 mL (if used) |
Limitations
The Cockcroft-Gault equation is less accurate in: acute kidney injury (creatinine is not at steady state), extreme body habitus (morbid obesity or severe cachexia), pediatric patients (Schwartz formula preferred), amputation or limb loss, and high-protein or vegan diets (affect creatinine production). When CrCl is borderline for a drug dose or contrast decision, consider cystatin C-based eGFR or 24-hour urine creatinine clearance for confirmation.
References
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.
Cigarroa RG, Lange RA, Williams RH, et al. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med. 1989;86(6 Pt 1):649–652.
ACR Manual on Contrast Media. American College of Radiology, 2023 edition.
Devine BJ. Gentamicin therapy. Drug Intell Clin Pharm. 1974;8:650–655.